Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Other financing activities (2016 - 2020)

Historic Other financing activities for Ernexa Therapeutics (ERNA) over the last 3 years, with Q4 2020 value amounting to -$1.2 million.

  • Ernexa Therapeutics' Other financing activities changed N/A to -$1.2 million in Q4 2020 from the same period last year, while for Dec 2020 it was $3000.0, marking a year-over-year change of. This contributed to the annual value of $135000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Ernexa Therapeutics reported Other financing activities of -$1.2 million as of Q4 2020.
  • In the past 5 years, Ernexa Therapeutics' Other financing activities ranged from a high of $1.2 million in Q1 2020 and a low of -$1.2 million during Q4 2020
  • Its 3-year average for Other financing activities is $4250.0, with a median of $5500.0 in 2016.
  • Data for Ernexa Therapeutics' Other financing activities shows a peak YoY increase of 590000.0% (in 2017) and a maximum YoY decrease of 34000.0% (in 2017) over the last 5 years.
  • Over the past 3 years, Ernexa Therapeutics' Other financing activities (Quarter) stood at $1000.0 in 2016, then skyrocketed by 5900.0% to $60000.0 in 2017, then plummeted by 2138.33% to -$1.2 million in 2020.
  • Its Other financing activities was -$1.2 million in Q4 2020, compared to $1.2 million in Q1 2020 and $60000.0 in Q4 2017.